Celator Pharmaceuticals (CPXX) Announces VYXEOS Phase 3 Met Primary Endpoint in High-Risk AML
Tweet Send to a Friend
Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) announced positive results from the Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
